FDA Gives First-Ever Approval to CAR T-Cell Therapy

A technician helps prepare CAR T cells at Dana-Farber's Connell and O'Reilly Families Cell Manipulation Core Facility.

A technician helps prepare CAR T cells at Dana-Farber’s Connell and O’Reilly Families Cell Manipulation Core Facility.

The Food and Drug Administration (FDA) announced today that a drug called CTL019 has become the first chimeric antigen receptor (CAR) T-cell therapy approved to treat a form of cancer.

The decision means the drug can be used as standard therapy for the treatment of pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL) that has relapsed or hasn’t responded to previous treatments. The approval, which follows the drug’s designation as a “breakthrough” therapy by the FDA, underscores the potential of CAR T-cell therapies to treat a wide range of cancers, researchers say.

The FDA ruling in favor of CTL019 is based on the results of a series of clinical trials that showed the therapy to be safe and effective in the patients tested. The largest such trial, known as the ELIANA trial, found that 83 percent of patients treated with CTL019 achieved complete remission – the disappearance of all signs of cancer – within three months of treatment.

CAR T-cell therapy, like all forms of cancer immunotherapy, seeks to sharpen and strengthen the immune system’s inherent cancer-fighting powers. It involves treating patients with modified versions of their own immune system T cells ­– white blood cells that help protect the body from disease.

To convert normal T cells into CAR T cells, technicians first extract T cells from a patient’s blood and genetically engineer them in a lab to produce proteins on their surface called chimeric antigen receptors, or CARs. The CARs serve a dual purpose: to enable the T cells to latch onto specific tumor cell proteins called antigens, and to signal the T cells to kill those tumor cells. The newly minted CAR T cells are allowed to reproduce in a lab until they number in the hundreds of millions, and they’re infused into the patient. If all goes as planned, the CAR T cells will continue to reproduce and serve as an effective fighting force against cancer cells.

The initial clinical trials of CAR T cell therapy have involved pediatric and adult patients with blood-based cancers such as leukemia, lymphoma, and multiple myeloma. Based on the therapy’s striking success in many patients, CAR T-cell therapy trials are now opening for certain types of solid tumors as well, beginning with glioblastoma brain tumors.

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
RT @BCRFcure: Today on #MLKDay, BCRF researcher Dr. Nikhil Wagle from @DanaFarber & breast cancer advocates are taking over our Instagram a…
Dana-Farber @danafarber
RT @lisa_scherber: Adolescent Girls Weekend has official begun! 27 Jimmy Fund teens will experience a weekend filled with beautiful memorie…
Dana-Farber @danafarber
RT @ChrisClea: Dr. Ann Partridge @YoungStrongDFCI leads @DanaFarber's programs for cancer survivors. More Survive Cancer, These Doctors Try…

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.